U.S. Entertainment Stock News

Rayonier Advanced Materials (RYAM) opened 2026 with Q1 revenue of US$319 million and a basic EPS loss of US$1.21, alongside trailing 12 month revenue of about US$1.4 billion and a basic EPS loss of US$7.08. Over recent quarters the company has seen revenue move from US$422.5 million in Q4 2024 to US$355.9 million in Q1 2025, US$340.0 million in Q2 2025, US$352.8 million in Q3 2025, US$417.5 million in Q4 2025 and now US$319 million in Q1 2026, while quarterly basic EPS losses have ranged...

Devon Energy (DVN) opened 2026 with Q1 revenue of US$4.3b and basic EPS of US$0.19 on net income of US$120m, setting a cautious tone for the new year. Over the past few quarters, the company has seen revenue move between US$3.8b and US$4.3b, while quarterly EPS has ranged from about US$0.77 to US$1.42. This has contributed to trailing twelve month EPS of US$3.63 on revenue of US$16.0b. Investors are therefore likely to focus on how much of that top line converts into profit as margins adjust...

Grab Holdings (NasdaqGS:GRAB) opened 2026 with Q1 revenue of US$955 million and basic EPS of US$0.03, setting a clear marker for how its ride hailing and delivery platform is currently translating scale into per share earnings. The company has seen quarterly revenue move from US$773 million in Q1 2025 to US$955 million in Q1 2026, while basic EPS has shifted from US$0.01 to US$0.03 over the same period. Trailing twelve month EPS now sits at US$0.09 on revenue of US$3.6 billion, giving...

Bioventus (BVS) opened 2026 with Q1 revenue of US$132.1 million and basic EPS of US$0.05, alongside trailing twelve month revenue of US$576.3 million and basic EPS of US$0.43 that reflect a period of positive net income. Over recent quarters the company has seen revenue range from US$123.9 million to US$157.9 million, while basic EPS moved from a loss of US$0.04 in early 2025 to US$0.22 in Q4 2025 and US$0.05 in the latest quarter, setting up a narrative that now hinges on how durable these...

Q1 2026 headline results and setup Corteva (CTVA) opened 2026 with Q1 revenue of US$4.9 billion and basic EPS of US$1.07, with trailing twelve month net income of US$1.25 billion giving investors a fuller view of the current earnings run rate. The company reported quarterly revenue of US$4.42 billion in Q1 2025 and US$4.91 billion in Q1 2026, while basic EPS moved from US$0.97 to US$1.07 over the same period as trailing net profit margins held close to 7%. With earnings growth forecasts...

Solventum (SOLV) opened Q1 2026 with revenue of US$2.0 billion and basic EPS of US$0.07, putting fresh numbers on the table for investors focused on how its earnings profile is evolving. Over the past few reporting periods, revenue has moved between US$2.1 billion in Q1 2025 and US$2.0 billion in Q1 2026, while basic EPS shifted from US$0.79 in Q1 2025 to US$0.07 in the latest quarter, with the trailing twelve months showing revenue of US$8.3 billion and basic EPS of US$8.22. This mix of...

Standard BioTools (LAB) has kicked off Q1 2026 with revenue of about US$21.1 million and a basic EPS loss of roughly US$0.04. This sets a cautious tone around how much of that top line is flowing through to the bottom line. The company has seen quarterly revenue move between roughly US$19.6 million and US$24.8 million since Q4 2024, while basic EPS has ranged from a loss of about US$0.08 to a profit of roughly US$0.04 over the same period. This underscores how sensitive margins have been to...

Tempus AI (TEM) opened Q1 2026 with revenue of US$348.1 million and a basic EPS loss of US$0.70, while trailing 12 month figures show US$1.4 billion in revenue and a basic EPS loss of US$1.72. This keeps the focus firmly on scaling rather than profitability. Over recent quarters the company has seen revenue move from US$255.7 million in Q1 2025 to US$348.1 million in Q1 2026, with basic EPS losses ranging between US$0.25 and US$0.70 per quarter across that period. For you as an investor, this...

CRISPR Therapeutics (NasdaqGM:CRSP) has expanded its lead CAR-T program, zugo-cel, into new autoimmune disease indications. The company advanced multiple in vivo liver-directed gene editing and siRNA programs into clinical development. CASGEVY, its gene-editing therapy, continues to see commercial traction, and a recent regulatory filing aims to extend its label to younger pediatric patients. A major convertible notes offering has strengthened the balance sheet and is funding a broader...

Intapp (NasdaqGS:INTA) has reported Q3 2026 revenue of US$146.0 million with a basic EPS loss of US$0.20, alongside net income excluding extra items of a US$15.5 million loss. The company has seen quarterly revenue progress from US$121.2 million in Q2 2025 to US$129.1 million in Q3 2025 and US$146.0 million in Q3 2026. Over the same periods, basic EPS moved from a US$0.13 loss to a US$0.04 loss and then a US$0.20 loss, setting up this quarter as another test of how quickly margins can move...

Bowman Consulting Group (BWMN) opened Q1 2026 with revenue of US$126.5 million and a basic EPS loss of US$0.22, alongside trailing twelve month EPS of US$0.62 on US$503.6 million of revenue. Over the past year, the company has seen revenue move from US$444.6 million to US$503.6 million on a trailing basis, while EPS shifted from US$0.16 to US$0.62, giving investors a clear view of how the top line and per share earnings have tracked together. Taken together with a trailing net margin that now...

Ferroglobe (NasdaqCM:GSM) opened 2026 with Q1 revenue of US$347.7 million and a basic EPS loss of US$0.04, alongside a trailing 12 month net loss of US$111.3 million on revenue of US$1.4 billion. Over recent quarters the company has seen revenue move between US$307.2 million and US$386.9 million, while quarterly basic EPS has ranged from a loss of US$0.04 to a loss of US$0.43 as profitability remained under pressure and margins stayed in the red. See our full analysis for Ferroglobe. With the...

BeOne Medicines (ONC) opened 2026 with Q1 revenue of US$1.5b and basic EPS of US$2.05, alongside net income of US$227.4 million. This sets a clear marker for how the business is currently converting its top line into earnings. Over the past year, the company has seen quarterly revenue move from US$1.1b in Q1 2025 to US$1.5b in Q1 2026, while basic EPS shifted from essentially flat at US$0.01 to US$2.05. This gives investors a straightforward read on how profitability is tracking against the...

Hackett Group (HCKT) has opened Q1 2026 with total revenue of US$67.8 million and basic EPS of US$0.17, alongside trailing twelve month revenue of US$292.5 million and EPS of US$0.53. These figures sit against a net profit margin of 4.8% versus 7.8% a year earlier. Over recent quarters the company has seen quarterly revenue move from US$76.2 million in Q1 2025 to US$77.6 million in Q2 2025, US$72.2 million in Q3 2025 and US$74.8 million in Q4 2025, before landing at US$67.8 million in Q1...

UWM Holdings (UWMC) opened 2026 with Q1 revenue of US$752.9 million and basic EPS of US$0.09, alongside trailing twelve month revenue of US$4.0 billion and basic EPS of US$0.27 that reflect the company’s move into profitability over the past year. The company has seen quarterly revenue range from US$613.4 million in Q1 2025 to US$1.0 billion in Q4 2025, with EPS swinging from a loss of US$0.08 in Q1 2025 to a profit of US$0.11 in Q2 2025 before settling at US$0.09 this quarter. This sets up a...

Lumentum Holdings (LITE) opened Q3 2026 with revenue of US$808.4 million and basic EPS of US$1.99, supported by net income of US$142.5 million. The company has seen revenue move from US$402.2 million in Q2 2025 to US$808.4 million in Q3 2026, while basic EPS shifted from a loss of US$0.88 to a gain of US$1.99. Trailing twelve month EPS stands at US$6.21 on revenue of US$2.5 billion. This combination of profitability and revenue scale puts the focus firmly on margins as results season...

Wondering if Bath & Body Works at around US$19.20 is a bargain or a value trap? This article focuses squarely on what the current price may be implying about the stock. The stock has risen 4.7% over the last week and 6.0% over the last month, yet year to date it shows a 7.4% decline and the 1 year return stands at 34.8% lower. This pattern may catch the eye of value focused investors. Recent coverage around specialty retail and consumer discretionary spending has put companies like Bath &...

Lineage (LINE) opened Q1 2026 with revenue of US$1.3 billion and a basic EPS loss of US$0.20. On a trailing 12 month basis, revenue stood at US$5.4 billion and basic EPS was a loss of US$0.63, alongside trailing 12 month revenue growth of 4.6% a year versus 11.3% for the broader US market. Over recent quarters, revenue has moved in a narrow band between US$1.29 billion and US$1.38 billion, while quarterly basic EPS has ranged from a loss of US$0.44 to a small profit of roughly US$0.03. This...

Some investors may be considering whether Douglas Dynamics at around US$45.42 is still offering value after a strong run, or whether much of the opportunity is already reflected in the current share price. The stock has recorded returns of 2.8% over 7 days, 8.1% over 30 days, 37.7% year to date and 83.6% over 1 year. This puts recent price action front and center for anyone weighing the balance between potential and risk. Recent coverage has highlighted Douglas Dynamics as a Machinery sector...

Uber Technologies (UBER) opened 2026 with Q1 revenue of US$13.2b and basic EPS of US$0.13, setting the tone for how investors assess profit quality after a year in which trailing twelve month EPS sat at US$4.12. The company reported quarterly revenue increasing from US$11.5b in Q1 2025 to US$13.2b in Q1 2026, while basic EPS moved from US$0.85 to US$0.13 over the same period, against a trailing net income base of US$8.5b. With margins firmly in focus after the past year's compression, this...

Medline (MDLN) opened 2026 by reporting Q1 revenue of about US$7.4b and net income of US$129m, with basic EPS of US$0.16 against a trailing twelve month EPS of US$1.14 that was generated on US$29.1b of revenue and US$966m of net income. Over the past few quarters the company has seen revenue move from US$6.8b in Q4 2024 to US$6.8b in Q1 2025, then to US$7.1b in Q3 2025, US$7.8b in Q4 2025 and finally US$7.4b in Q1 2026, while quarterly basic EPS shifted from US$0.02 in Q4 2024 to US$0.02 in...

If you are wondering whether IPG Photonics at around US$101.94 is a bargain or a potential value trap, you are not alone. The stock has pulled back 10.0% over the last week and 7.7% over the last month, yet it still stands 36.2% higher year to date and 76.1% over the last year, compared with 3-year and 5-year returns of 9.5% and 45.6% declines. Those swings come alongside ongoing attention on IPG Photonics as a key player in high performance fiber lasers and related photonics solutions. This...

CS Disco (LAW) has reported Q1 2026 revenue of US$41.9 million with a basic EPS loss of US$0.15, setting the stage for another quarter where investors are weighing top line progress against ongoing losses. The company has seen quarterly revenue move from US$36.7 million in Q1 2025 to US$41.9 million in Q1 2026, while quarterly basic EPS over that period has ranged from a loss of US$0.19 to a loss of US$0.15, keeping the focus firmly on when margins might begin to meaningfully narrow. With the...

Investors may be wondering if APA at US$38.30 still offers value after a strong run, or if most of the opportunity is already in the price. The stock has a 7 day return of a 5.0% decline and a 30 day return of an 11.0% decline, yet it shows a 51.0% return year to date and 157.7% over the last year, which can change how investors think about both upside and risk. Over the last three and five years, APA has returns of 30.8% and 109.7%. These figures keep the stock on many watchlists even after...